Investig Clin Urol.  2019 May;60(3):139-141. 10.4111/icu.2019.60.3.139.

Liquid biopsy: Where did it come from, what is it, and where is it going?

• Morgan TM

• KMID: 2444266
• DOI: http://doi.org/10.4111/icu.2019.60.3.139

Abstract

No abstract available.

MeSH Terms

Biopsy*

Reference

1. Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, et al. Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature. Mol Cancer Res. 2018; 16:643–654.

2. Scher HI, Graf RP, Schreiber NA, McLaughlin B, Jendrisak A, Wang Y, et al. Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer. Cancer Res. 2017; 77:5687–5698.

3. Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, et al. Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget. 2017; 8:89848–89866.

4. Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst. 2017; 109.

5. Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, et al. Circulating Tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018; 8:444–457.

6. Torga G, Pienta KJ. Patient-paired sample congruence between 2 commercial liquid biopsy tests. JAMA Oncol. 2018; 4:868–870.

7. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018; 359:926–930.